SCPH - Scpharmaceuticals Inc Stock Price, Fair Value and News

$3.39+0.08 (+2.42%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SCPH Price Action

Last 7 days

6.3%

Last 30 days

0.9%

Last 90 days

-34.6%

Trailing 12 Months

-47.0%

SCPH RSI Chart

SCPH Valuation

Market Cap

169.6M

Price/Earnings (Trailing)

-2.12

Price/Sales (Trailing)

5.6

Price/Free Cashflow

-2.77

SCPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SCPH Fundamentals

SCPH Revenue

Revenue (TTM)

30.3M

Rev. Growth (Yr)

164.12%

Rev. Growth (Qtr)

24.48%

SCPH Earnings

Earnings (TTM)

-80.1M

Earnings Growth (Yr)

-124.54%

Earnings Growth (Qtr)

-105.41%

SCPH Profitability

Operating Margin

69.72%

Return on Equity

-260.88%

Return on Assets

-64.06%

Free Cashflow Yield

-36.06%

SCPH Investor Care

Shares Dilution (1Y)

39.54%

Diluted EPS (TTM)

-1.9

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.6M	24.0M	30.3M	0
2023	0	0	0	13.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Scpharmaceuticals Inc

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

CEO	Mr. John H. Tucker
WEBSITE	scpharmaceuticals.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	96

Scpharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Scpharmaceuticals Inc? What does SCPH stand for in stocks?

SCPH is the stock ticker symbol of Scpharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Scpharmaceuticals Inc (SCPH)?

As of Fri Dec 20 2024, market cap of Scpharmaceuticals Inc is 169.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SCPH stock?

You can check SCPH's fair value in chart for subscribers.

Is Scpharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SCPH is over valued or under valued. Whether Scpharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Scpharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SCPH.

What is Scpharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, SCPH's PE ratio (Price to Earnings) is -2.12 and Price to Sales (PS) ratio is 5.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SCPH PE ratio will change depending on the future growth rate expectations of investors.